tbuckley/cabot-search huggingface dataset:
HGG-07. THREE SUCCESSIVE BIOPSIES DEMONSTRATE CLONAL EVOLUTION IN A MULTIPLY-RECURRENT PEDIATRIC GLIOFIBROMA
Authors: Kristiyana Kaneva, Kee Kiat Yeo, Debra Hawes, Jianling Ji, Jaclyn A Biegel, Marvin D Nelson, Stefan Bluml, Mark D Krieger, Anat Erdreich-Epstein
Journal: Neuro-Oncology (2019)

Gliofibroma is a rare central nervous system (CNS) tumor with yet-undescribed molecular characteristics. We describe a 20-month-old boy presenting with a large infiltrative gliofibroma arising in the left midbrain. The tumor was partially resected and the pathology was consistent with gliofibroma with low proliferation. Magnetic resonance spectroscopy of the remaining mass was consistent with a high-grade tumor. Molecular findings were significant for a BRAFV600E mutation and homozygous deletion of CDKN2A. The patient was treated with targeted therapy using a combination of the BRAFV600E inhibitor vemurafenib and the MEK inhibitor, trametinib, with rapid clinical response. Tumor shrinkage was sustained for at least 12 months. Routine MRI at 15 months revealed marked tumor regrowth with pathology from subsequent resection demonstrating areas of low-grade morphology as well as areas with high-grade features. Molecular findings on the initial recurrence were notable for new PDGFRA (Asp842Tyr) and PTPN11 (Ala72Val) mutations in addition to the original genetic alterations. The patient received radiation therapy, but became symptomatic shortly prior to completion. MRI demonstrated new infiltrative tumor anterior to the lateral ventricle, outside the radiation field and extensive subependymal infiltration. Resection of the new mass revealed two new mutations in TP53 (Arg196Gln) and PIK3CA (His1047Arg), in addition to the four previous alterations. To our knowledge, this is the first report on gliofibroma with extensive molecular characterization and the first reported high-grade glioma with molecular data from three successive biopsies. The observed serial acquisition of new mutations on subsequent recurrent specimens is consistent with clonal evolution of disease. The availability of three sets of molecular results on repeat biopsies is unique even to the broader diagnosis of high-grade glioma and sheds light on the biology of recurrence.
BSTM-01. POTENT ANTI-TUMOR EFFICACY OF PALBOCICLIB IN TREATMENT-NAÏVE H3.3K27M-MUTANT DIFFUSE INTRINSIC PONTINE GLIOMA
Authors: Yu Sun, Ye Sun, Liwei Zhang, Qiaoran Xi
Journal: Neuro-Oncology (2019)

Diffuse intrinsic pontine glioma (DIPG) is a rare and fatal pediatric brain cancer without cure. DIPG has high percentage histone mutation at K27M on histone H3 locus, which is believed to be one of the drivers of the tumorigenesis. Dysregulation of G1/S cell cycle checkpoint is more enriched in the H3.3K27M mutant subgroup. In this study, we reported that palbociclib (PD0332991), a specific and cytostatic inhibitor of CDK4/6, effectively suppress the growth of treatment-naïve patient derived DIPG cells in vitro and in vivo. First, we established patient derived cell lines from treatment-naïve specimens, which all have H3.3K27M mutation. And our DIPG cell lines with H3.3K27M mutation have high CDK4/6 expression. Then, we showed that depletion of CDK4or CDK6inhibits DIPG cells growth and blocks G1/S transition. Furthermore, palbociclib effectively repressed all 8 cell lines self-renewal, proliferation and cell cycle progression from G1 to S phase in vitro. Transcriptome analysis showed that palbociclibnot only blocks G1/S transition, it also blocks other oncogenic targets such as Myc. Finally, palbociclib activity was assayed in vivo against DIPG orthotropic xenografts to demonstrate the high efficiency of blocking tumor growth. Our findings revealed that palbociclib could be the therapy strategy for DIPG, especially for treatment-naïve patients.
Neocortical Projection Neurons Instruct Inhibitory Interneuron Circuit Development in a Lineage-Dependent Manner
Authors: Jason C. Wester, Vivek Mahadevan, Christopher T. Rhodes, Daniela Calvigioni, Sanan Venkatesh, Dragan Maric, Steven Hunt, Xiaoqing Yuan, Yajun Zhang, Timothy J. Petros, Chris J. McBain
Journal: Neuron (2019)
Opioid Prescription After Surgery
Authors: Yuko Kurokawa, Tomohiro Kurokawa, Tetsuya Tanimoto
Journal: JAMA Surgery (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA — update 2018
Authors: Yair Lotan, Trinity J. Bivalacqua, Tracy Downs, William Huang, Jeffrey Jones, Ashish M. Kamat, Badrinath Konety, Per-Uno Malmström, James McKiernan, Michael O’Donnell, Sanjay Patel, Kamal Pohar, Matthew Resnick, Alexander Sankin, Angela Smith, Gary Steinberg, Edouard Trabulsi, Michael Woods, Siamak Daneshmand
Journal: Nature Reviews Urology (2019)

Blue light cystoscopy (BLC) with hexaminolevulinate (HAL) during transurethral resection of bladder cancer improves detection of non-muscle-invasive bladder cancer (NMIBC) and reduces recurrence rates. Flexible BLC was approved by the FDA in 2018 for use in the surveillance setting and was demonstrated to improve detection. Results of a phase III prospective multicentre study of blue light flexible cystoscopy (BLFC) in surveillance of intermediate-risk and high-risk NMIBC showed that 20.6% of malignancies were identified only by BLFC. Improved detection rates in the surveillance setting are anticipated to lead to improved clinical outcomes by reducing future recurrences and earlier identification of tumours that are unresponsive to therapy. Thus, BLFC has a role in surveillance cystoscopy, and determining which patients will benefit from BLFC and optimal and cost-effective ways of incorporating this technology into surveillance cystoscopy must be developed. In this Consensus Statement, experts in the field detail the current evidence regarding blue light flexible cystoscopy for bladder cancer surveillance and make recommendations regarding its use on the basis of conclusions arrived at during the panel discussions at a consensus meeting.
Abstract 18879: Discordance between ICD-9 Coded Myocardial Infarction and Adjudicated Diagnosis According to the Universal Definition of Myocardial Infarction
Authors: Jorge Díaz-Garzón, Yader Sandoval, Stephen W Smith, Sara A Love, Karen Schulz, Sarah E Thordsen, Benjamin K Johnson, Brian Driver, Katherine Jacoby, Michelle D Carlson, Kenneth W Dodd, Johanna Moore, Nathaniel L Scott, Charles A Bruen, Fred S Apple
Journal: Circulation (2016)

Introduction: The International Classification of Diseases (ICD) codes facilitate quality review evaluations. However, despite the global endorsement by cardiology societies, the Third Universal De...
‘It's like the bad guy in a movie who just doesn't die’: a qualitative exploration of young people's adaptation to eczema and implications for self‐care
Authors: D. Ghio, I. Muller, K. Greenwell, A. Roberts, A. McNiven, S.M. Langan, M. Santer
Journal: British Journal of Dermatology (2019)

Eczema is a common childhood inflammatory skin condition, affecting more than one in five children. A popular perception is that children ‘outgrow eczema’, although epidemiological studies have shown that, for many, eczema follows a lifelong episodic course. To explore the perceptions of young people about the nature of their eczema and how these perceptions relate to their self‐care and adapting to living with eczema. This is a secondary inductive thematic analysis of interviews conducted for Healthtalk.org. In total 23 interviews with young people with eczema were included. Of the 23 participants, 17 were female and six male, ranging from 17 to 25 years old. Participants generally experienced eczema as an episodic long‐term condition and reported a mismatch between information received about eczema and their experiences. The experience of eczema as long term and episodic had implications for self‐care, challenging the process of identifying triggers of eczema flare‐ups and evaluating the success of treatment regimens. Participants’ experiences of eczema over time also had implications for adaptation and finding a balance between accepting eczema as long term and hoping it would go away. This linked to a gradual shift in treatment expectations from ‘cure’ to ‘control’ of eczema. For young people who continue to experience eczema beyond childhood, a greater focus on self‐care for a long‐term condition may be helpful. Greater awareness of the impact of early messages around ‘growing out of’ eczema and provision of high‐quality information may help patients to manage expectations and support adaptation to treatment regimens. What's already known about this topic? There is a common perception that people ‘grow out of’ eczema, but for many people eczema follows a lifelong episodic course. Qualitative work has shown that parents can find that being told their child will grow out of eczema is dismissive, and that they have difficulty with messages about ‘control not cure’ of eczema. It is unclear how young people perceive their eczema and the implications of this perception for their adaptation and self‐care. What does this study add? The message that many people ‘grow out of’ eczema has a potentially detrimental effect for young people where the condition persists. This has implications for young people's perceptions of their eczema, their learning to self‐care and how they adapt to living with eczema and eczema treatments. What are the clinical implications of this work? Clinicians need to promote awareness among young people that eczema is a long‐term episodic condition in order to engage them with effective self‐care. Young people transitioning to self‐care need evidence‐based information that is specific and relatable to them.
Rational design of anti-GITR-based combination immunotherapy
Authors: Roberta Zappasodi, Cynthia Sirard, Yanyun Li, Sadna Budhu, Mohsen Abu-Akeel, Cailian Liu, Xia Yang, Hong Zhong, Walter Newman, Jingjing Qi, Phillip Wong, David Schaer, Henry Koon, Vamsidhar Velcheti, Matthew D. Hellmann, Michael A. Postow, Margaret K. Callahan, Jedd D. Wolchok, Taha Merghoub
Journal: Nature Medicine (2019)
Consumption of Alcohol Beverages and Binge Drinking Among Pregnant Women Aged 18–44 Years — United States, 2015–2017
Authors: Clark H. Denny, Cristian S. Acero, Timothy S. Naimi, Shin Y. Kim
Journal: MMWR Morbidity and Mortality Weekly Report (2019)

Drinking alcohol during pregnancy can cause fetal alcohol spectrum disorders (FASDs), including birth defects that involve central nervous system impairment, behavioral disorders, and impaired intellectual development, which can lead to difficulties with school and employment. A recent study in four U.S. communities found a 1.1%-5.0% prevalence of FASDs among first-grade students (1). Drinking during pregnancy might also be a risk factor for other adverse pregnancy and birth outcomes, including miscarriage and stillbirth (2). CDC estimated the prevalence of self-reported current drinking (at least one alcohol drink in the past 30 days) and binge drinking (consuming four or more drinks on at least one occasion in the past 30 days) among pregnant women aged 18-44 years, using 2015-2017 data from the Behavioral Risk Factor Surveillance System (BRFSS). Current drinking and binge drinking in the past 30 days were reported by 11.5% and 3.9% of pregnant women, respectively. Among pregnant women who binge drink, the average frequency of binge drinking in the past 30 days was 4.5 episodes, and the average intensity of binge drinking (the average largest number of drinks reported consumed on any occasion among binge drinkers) was 6.0 drinks. Increased implementation of evidence-based community-level and clinic-level interventions, such as universal alcohol screening and brief counseling in primary and prenatal care, could decrease the prevalence of drinking during pregnancy, which might ultimately reduce the prevalence of FASDs and other adverse pregnancy and birth outcomes.
Chemo‐Photothermal Therapy: Nanogold Flower‐Inspired Nanoarchitectonics Enables Enhanced Light‐to‐Heat Conversion Ability for Rapid and Targeted Chemo‐Photothermal Therapy of a Tumor (Adv. Healthcare Mater. 8/2019)
Authors: Jing Liu, Fenfen Zhai, Hong Zhou, Wenrong Yang, Shusheng Zhang
Journal: Advanced Healthcare Materials (2019)

In article number 1801300 by Hong Zhou, Shusheng Zhang, and co-workers, a new member of photothermal materials-nanogold flower decorated graphene oxide composites is proposed with impressive photothermal performance. It is a versatile nanocarrier for chemo-photothermal therapy of tumors, promoting the development of efficient nanocarriers for wide bio-applications.
EPEN-06. YAP1 SUBGROUP SUPRATENTORIAL EPENDYMOMA REQUIRES TEAD AND NUCLEAR FACTOR I-MEDIATED TRANSCRIPTIONAL PROGRAMS FOR TUMORIGENESIS
Authors: Kristian Pajtler, Yiju Wei, Konstantin Okonechniov, Mikaella Vouri, Felix Sahm, Jens Bunt, David Jones, Andrey Korshunov, Peter Lichter, Stefan Pfister, Marcel Kool, Wei Li, Daisuke Kawauchi
Journal: Neuro-Oncology (2019)

Ependymoma (EPN) is one of the most aggressive pediatric brain tumors, often arising in the supratentorial (ST) region. Our previous DNA methylation profiling study has identified ST-EPN subgroups that are characterized by YAP1-related fusions through genomic structural rearrangements (hereafter called as ST-EPN-YAP1). No reports of amplification and hyper-activation of the YAP1 gene in ST-EPN-YAP1s postulate that YAP1-related fusions could have unique oncogenic function(s) in this type of cancer. Nevertheless, the lack of adequate models for ST-EPN-YAP1 had hindered the discovery of YAP1-fusion-specific molecular mechanisms in EPN tumorigenesis and the development of effective targeted therapies for these tumors. Most recently, we developed a murine ST-EPN-YAP1 model by forced expression of YAP1-MAMLD1, the most dominant type of the fusion proteins in ST-EPN-YAP1 into cortical progenitors using in utero electroporation. Detailed histological analysis suggest that tumors arose from Pax6-positive neural stem cells, which is highly consistent with the highest expression of PAX6 in human ST-EPN-YAP1s across all EPN subgroups. MAMLD1-driven nuclear localization of the fusion protein is strongly associated with tumorigenesis. To investigate oncogenic functions of YAP1-MAMLD1, we performed a ChIP-seq analysis on human ST-EPN-YAP1 primary tumors with an anti-YAP1 antibody. Intriguingly, ST-EPN-YAP1-specific enhancers enriched for YAP1 peaks exhibited abundant transcriptional factor binding motifs of nuclear factor I and TEADs. Co-immunoprecipitation revealed that both TEAD and NFIA/B interact with YAP1-MAMLD1. Both the mutation of the TEAD binding site in the YAP1 fusion and dominant-negative inhibition of NFI proteins prevented tumor induction in mice. Collectively, we demonstrated that YAP1-MAMLD1 function as an oncogenic driver in ST-EPN-YAP1s through recruitment of TEAD and NFI transcriptional factors.
The correlations of tumor mutational burden among single-region tissue, multi-region tissues and blood in non-small cell lung cancer
Authors: Yaxiong Zhang, Lianpeng Chang, Yunpeng Yang, Wenfeng Fang, Yanfang Guan, Aiwei Wu, Shaodong Hong, Huaqiang Zhou, Gang Chen, Xi Chen, Shen Zhao, Qiufan Zheng, Hui Pan, Lanjun Zhang, Hao Long, Haoxian Yang, Xin Wang, Zhesheng Wen, Junye Wang, Hong Yang, Xuefeng Xia, Yuanyuan Zhao, Xue Hou, Yuxiang Ma, Ting Zhou, Zhonghan Zhang, Jianhua Zhan, Yan Huang, Hongyun Zhao, Ningning Zhou, Xin Yi, Li Zhang
Journal: Journal for ImmunoTherapy of Cancer (2019)

High-level tissue tumor mutational burden (tTMB) or blood TMB (bTMB) are associated with better response of immunotherapy in non-small cell lung cancer (NSCLC) patients. However, the correlations of single-region tTMB, multi-region tTMB and bTMB remain to be determined. Moreover, whether intratumor heterogeneity (ITH) has impact on TMB should be clarified. We collected multi-region tumor tissues with matched blood from 32 operative NSCLC and evaluated single-region tTMB, multi-region tTMB and bTMB through a 1021-gene panel sequencing. TMB of > 9 mutations/Mb was classified as high. Besides, we used tTMB fold-change to evaluate the influence of the enrolled region number on tTMB. We found both of single-region tTMB and bTMB showed strong correlations with multi-region tTMB, while the former correlated better (Pearson r = 0.94, P = 2E-84; Pearson r = 0.47, P = 0.0067). It showed extremely high specificity (100%) but low sensitivity (43%) when using bTMB to define TMB-high patients, while most false-negative predictions were in early-stage patients. Compared to single region, we found significantly enhanced tTMB fold-change if taking multi-regions for consideration. However, it showed insignificant tTMB fold-change increase if the included regions' number more than three. Moreover, ITH-high patients had significantly higher tTMB fold-change compared with ITH-low patients (2.32 vs. 1.02, P = 8.879e-05). The conversion rate of tTMB level (tTMB-low to tTMB-high) was numerically higher in ITH-high group than that in ITH-low group (16.67% vs. 3.84%). In summary, single-region tTMB has stronger correlation with multi-region tTMB compared with bTMB. ITH has an impact on tTMB, especially in high-level ITH patients.
Circulating Tumor Cells as a Tool for Assessing Tumor Heterogeneity
Authors: Marta Tellez-Gabriel, Marie-Françoise Heymann, Dominique Heymann
Journal: Theranostics (2019)

Tumor heterogeneity is the major cause of failure in cancer prognosis and prediction.Accurately detecting heterogeneity for the development of biomarkers and the detection of the clones resistant to therapy is one of the main goals of contemporary medicine.Metastases belong to the natural history of cancer.The present review gives an overview on the origin of tumor heterogeneity.Recent progress has made it possible to isolate and characterize circulating tumor cells (CTCs), which are the drivers of the disease between the primary sites and metastatic foci.The most recent methods for characterizing CTCs are summarized and we discuss the power of CTC profiling for analyzing tumor heterogeneity in early and advanced diseases.
Restrictive strategy versus usual care for cholecystectomy in patients with gallstones and abdominal pain (SECURE): a multicentre, randomised, parallel-arm, non-inferiority trial
Authors: Aafke H van Dijk, Sarah Z Wennmacker, Philip R de Reuver, Carmen S S Latenstein, Otmar Buyne, Sandra C Donkervoort, Quirijn A J Eijsbouts, Joos Heisterkamp, Klaas in 't Hof, Jan Janssen, Vincent B Nieuwenhuijs, Henk M Schaap, Pascal Steenvoorde, Hein B A C Stockmann, Djamila Boerma, Gert P Westert, Joost P H Drenth, Marcel G W Dijkgraaf, Marja A Boermeester, Cornelius J H M van Laarhoven
Journal: The Lancet (2019)
Enhancement of Bleeding Control 1.0 to Reach Communities at High Risk for Urban Gun Violence
Authors: Erin G. Andrade, Jane M. Hayes, Laurie J. Punch
Journal: JAMA Surgery (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Percutaneous Coronary Intervention vs Coronary Artery Bypass Grafting
Authors: Mario Gaudino, David P. Taggart
Journal: JAMA Cardiology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
High‐dose intravenous immunoglobulin as adjuvant treatment for grade <scp>IV</scp> acute cutaneous graft‐versus‐host disease
Authors: S.K. Blanchard, K.M. Sullivan, J.N. Hooten, Z. E. Holcomb, K. Rowe Nichols, M.A. Selim, C.L. Rao, R.P. Hall, N.J. Chao, A.R. Cardones
Journal: British Journal of Dermatology (2019)